REFLECT – 3 Study
Description: Previous research has shown that rosiglitazone, a diabetes drug, in a new extended release formulation, may have benefit in Alzheimer's patients and that this benefit may be related to a patient's genetic makeup. This study will test the efficacy and safety of the new extended release formulation of rosiglitazone when added to standard approved drug treatment with Acetylcholinesterase Inhibitors (AChEI).
Study Length: Approximately 1 year
Study Requirements: 50 -90 years of age, Diagnosis of Probable AD, Not currently taking Namenda, Have a reliable study partner
Contact: MaryAnn Oakley at 412-692-2721
Alzheimer Disease Neuroimaging Study (ADNI)
Description
This study will determine whether imaging of the brain (through MRI and PET scans) every 6 months can help predict the onset and monitor the progression of AD. Participants will undergo repeated brain MRI's, cognitive testing, and have blood and urine analysis for biomarkers. PET scans and lumbar punctures are study options.
Study Length: 24-36 months
Study Requirements: 77-90 years of age, Diagnosis of Mild Cognitive Impairment (MCI), Diagnosis of Early AD, Fluent in English,Have a reliable study partner.
Compensation: Participants will receive $100 per visit and an additional $200 for the optional lumbar puncture.
Contact: This Study is no longer recruiting.
DHA - Omega-3 Fatty Acid
Description: This study will determine whether DHA, an Omega-3 fatty acid, supplementation can slow the progression of cognitive and functional decline over an 18 month period in patients with mild to moderate AD. A subgroup will have MRIs and 2 lumbar punctures with consent.
Study Length: 18 months
Study Requirements: 50 years of age or older, Diagnosis of Probable AD, Have a reliable study partner
Compensation: Participants will receive $200 for undergoing the optional lumbar puncture.
Contact: This Study is no longer recruiting.
ONO-AMEND Study
Description
The AMEND (Astrocyte Modulator Evaluation of Neurodegenerative Disease) Study evaluates the safety and effectiveness of an investigational medication that may have a beneficial effect on astrocytes, the cells in the brain that support nerve cell function. People with Alzheimer's disease who meet the following criteria would be eligible:
Study Requirements: between 50 and 90 years of age, have a responsible caregiver (spouse, family member, friend, etc. who is able to attend all clinic visits and answer questions about the volunteer), are either not taking any medication for Alzheimer's disease or are taking a stable dose (90 days) of Aricept or Exelon (FDA approved medications for Alzheimer's disease), are not taking Namenda or Reminyl (other FDA-approved medications for Alzheimer's disease) .
Study Coordinator: Beth Sarles
Contact: This Study is no longer recruiting.
MPC-7869 Efficacy Study in Patients with Alzheimer's
Description
Some early research studies have shown that people who take anti-inflammatory drugs (such as aspirin or ibuprofen) may have a lower chance of developing Alzheimer’s disease. One of these anti-inflammatory drugs is called flurbiprofen. This drug is approved for use by the FDA. An ingredient of flurbiprofen, called MPC-7869, has been chosen to be studied as a possible treatment for Alzheimer’s disease. People with Alzheimer's disease who meet the following criteria might be eligible:
Study Requirements: Age 55+ and community dwelling, Have a study Partner (caregiver) with whom they have contact at least 4 days a week, Speak English.
Study Coordinator: Donna Simpson
Contact: This study is no longer recruiting.
Huperzine A Study
Description
Huperzine A is a natural product extracted from a Chinese herb. It is used in China to treat Alzheimer's disease, and it is available over the counter in the U.S. as an herbal supplement. This study will test whether Huperzine A can help the symptoms of Alzheimer's disease. The Huperzine A used in this study is high quality without other substances in the supplement. Volunteers must:
Study Requirements: have mild to moderate Alzheimer's disease, be age 55 or older, speak English, not currently take a medication for Alzheimer's disease (such as the FDA-approved drugs Aricept, Exelon or Reminyl), have a study partner-a friend or relative who can accompany the volunteer to all clinic visits and answer questions about him/her.
Study Coordinator: Thomas Baumgartner
Contact: This Study is no longer recruiting.
AAB-001-201 in Patients with Mild to Moderate Alzheimer¹s Disease
Description
The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate AD. AAB-001 is an antibody which binds to and clears beta amyloid peptides. It is designed to provide antibodies to beta amyloid directly to the patient, rather than requiring the patient to mount his/her own individual response. It is believed that this approach may eliminate the need for the patient to mount an immune response to beta amyloid. Animal studies have shown that this approach is equally effective in clearing beta amyloid from the brain as traditional active immunization methods. Participation in this study is approximately 2 years.
Contact: This Study is no longer recruiting.